- 現金殖利率: 5.77%、總殖利率: 5.77%、5年平均現金配發率: 110.51%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 (5) | 3.64 | 180.0 | 3.00 | 0.0 | 0.00 | 0 | 82.42 | -64.29 | 0.00 | 0 | 82.42 | -64.29 |
| 2024 (4) | 1.30 | 23.81 | 3.00 | 50.0 | 0.00 | 0 | 230.77 | 21.15 | 0.00 | 0 | 230.77 | 21.15 |
| 2023 (3) | 1.05 | -69.03 | 2.00 | 100.0 | 0.00 | 0 | 190.48 | 545.71 | 0.00 | 0 | 190.48 | 545.71 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 26Q1 (8) | 0.16 | -86.99 | -84.0 | 0.99 | -59.09 | -27.74 | 0.16 | -95.64 | -84.0 |
| 25Q4 (7) | 1.23 | -54.44 | 379.55 | 2.42 | 108.62 | 15.79 | 3.67 | 50.41 | 180.15 |
| 25Q3 (6) | 2.70 | 316.0 | 1321.05 | 1.16 | -6.45 | 24.73 | 2.44 | 1076.0 | 39.43 |
| 25Q2 (5) | -1.25 | -225.0 | -152.97 | 1.24 | -9.49 | -21.52 | -0.25 | -125.0 | -116.03 |
| 25Q1 (4) | 1.00 | 327.27 | 0.0 | 1.37 | -34.45 | 0.0 | 1.00 | -23.66 | 0.0 |
| 24Q4 (3) | -0.44 | -331.58 | 0.0 | 2.09 | 124.73 | 0.0 | 1.31 | -25.14 | 0.0 |
| 24Q3 (2) | 0.19 | -91.95 | 0.0 | 0.93 | -41.14 | 0.0 | 1.75 | 12.18 | 0.0 |
| 24Q2 (1) | 2.36 | 0.0 | 0.0 | 1.58 | 0.0 | 0.0 | 1.56 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/6 | 4.22 | 17.62 | 0.28 | 21.75 | -8.86 | 11.11 | N/A | - | ||
| 2026/5 | 3.59 | 8.5 | -4.91 | 17.53 | -10.81 | 11.45 | N/A | - | ||
| 2026/4 | 3.31 | -27.5 | -25.71 | 13.95 | -12.22 | 10.19 | N/A | - | ||
| 2026/3 | 4.56 | 95.91 | -5.97 | 10.64 | -6.96 | 10.64 | 1.72 | - | ||
| 2026/2 | 2.33 | -37.99 | -20.47 | 6.08 | -7.69 | 11.35 | 1.62 | - | ||
| 2026/1 | 3.75 | -28.72 | 2.5 | 3.75 | 2.5 | 12.78 | 1.43 | - | ||
| 2025/12 | 5.27 | 40.04 | -2.37 | 48.51 | 2.54 | 13.04 | 1.32 | - | ||
| 2025/11 | 3.76 | -6.36 | -12.77 | 43.25 | 3.17 | 11.95 | 1.44 | - | ||
| 2025/10 | 4.02 | -3.87 | 5.37 | 39.49 | 5.0 | 11.86 | 1.45 | - | ||
| 2025/9 | 4.18 | 14.0 | 14.37 | 35.47 | 4.96 | 11.61 | 1.52 | - | ||
| 2025/8 | 3.66 | -2.65 | 8.38 | 31.29 | 3.82 | 11.64 | 1.52 | - | ||
| 2025/7 | 3.76 | -10.5 | 14.92 | 27.63 | 3.24 | 11.74 | 1.51 | - | ||
| 2025/6 | 4.21 | 11.51 | -3.85 | 23.87 | 1.61 | 12.43 | 1.4 | - | ||
| 2025/5 | 3.77 | -15.22 | -17.0 | 19.66 | 2.86 | 13.07 | 1.33 | - | ||
| 2025/4 | 4.45 | -8.24 | 37.97 | 15.89 | 9.06 | 12.23 | 1.42 | - | ||
| 2025/3 | 4.85 | 65.71 | -13.91 | 11.44 | 0.84 | 11.44 | 1.49 | 本月營收減少主係去年子公司-台新藥認列權利金收入美金4百萬元。 | ||
| 2025/2 | 2.93 | -20.07 | 19.1 | 6.59 | 15.41 | 11.98 | 1.42 | - | ||
| 2025/1 | 3.66 | -32.12 | 12.63 | 3.66 | 12.63 | 13.37 | 1.27 | - | ||
| 2024/12 | 5.39 | 25.12 | 9.1 | 47.31 | 8.49 | 13.52 | 1.27 | - | ||
| 2024/11 | 4.31 | 13.12 | 36.69 | 41.92 | 8.42 | 11.77 | 1.45 | - | ||
| 2024/10 | 3.81 | 4.33 | -5.34 | 37.61 | 5.91 | 10.84 | 1.58 | - | ||
| 2024/9 | 3.65 | 8.02 | -5.19 | 33.8 | 7.34 | 10.31 | 1.83 | - | ||
| 2024/8 | 3.38 | 3.21 | -15.77 | 30.14 | 9.09 | 11.03 | 1.71 | - | ||
| 2024/7 | 3.28 | -25.13 | -4.38 | 26.76 | 13.32 | 12.2 | 1.54 | - | ||
| 2024/6 | 4.38 | -3.73 | -1.65 | 23.49 | 16.33 | 12.15 | 1.47 | - | ||
| 2024/5 | 4.55 | 40.93 | 37.77 | 19.11 | 21.41 | 13.4 | 1.33 | - | ||
| 2024/4 | 3.22 | -42.75 | 3.3 | 14.57 | 17.07 | 11.32 | 1.58 | - | ||
| 2024/3 | 5.63 | 129.29 | 46.06 | 11.34 | 21.68 | 11.34 | N/A | 本月營收增加主係合併子公司台新藥認列Eyenovia授權金 | ||
| 2024/2 | 2.46 | -24.42 | -11.3 | 5.71 | 4.47 | 10.65 | N/A | - | ||
| 2024/1 | 3.25 | -34.24 | 20.7 | 3.25 | 20.7 | 11.35 | N/A | - | ||
| 2023/12 | 4.94 | 56.76 | 32.4 | 43.6 | 15.79 | 12.12 | N/A | - | ||
| 2023/11 | 3.15 | -21.66 | -7.72 | 38.66 | 13.97 | 11.03 | N/A | - | ||
| 2023/10 | 4.03 | 4.5 | 13.99 | 35.51 | 16.4 | 11.89 | N/A | - | ||
| 2023/9 | 3.85 | -4.02 | -4.83 | 31.48 | 16.71 | 11.29 | N/A | - | ||
| 2023/8 | 4.01 | 17.15 | 43.84 | 27.63 | 20.52 | 11.89 | N/A | - | ||
| 2023/7 | 3.43 | -22.98 | 0.71 | 23.62 | 17.29 | 11.17 | N/A | - | ||
| 2023/6 | 4.45 | 34.85 | 43.34 | 20.19 | 20.66 | 10.87 | N/A | - | ||
| 2023/5 | 3.3 | 5.67 | 37.74 | 15.74 | 15.49 | 10.28 | N/A | - | ||
| 2023/4 | 3.12 | -19.05 | 8.24 | 12.44 | 10.75 | 9.75 | N/A | - | ||
| 2023/3 | 3.86 | 39.23 | 12.66 | 9.32 | 11.62 | 9.32 | N/A | - | ||
| 2023/2 | 2.77 | 2.84 | 34.08 | 5.46 | 10.89 | 9.2 | N/A | - | ||
| 2023/1 | 2.69 | -27.86 | -5.84 | 2.69 | -5.84 | 9.84 | N/A | - | ||
| 2022/12 | 3.73 | 9.24 | 16.2 | 37.66 | 19.82 | 10.68 | N/A | - | ||
| 2022/11 | 3.42 | -3.22 | 9.91 | 33.92 | 20.24 | 11.0 | N/A | - | ||
| 2022/10 | 3.53 | -12.75 | 37.48 | 30.5 | 21.52 | 10.37 | N/A | - | ||
| 2022/9 | 4.05 | 45.06 | 44.8 | 26.97 | 19.7 | 10.24 | N/A | - | ||
| 2022/8 | 2.79 | -17.96 | 31.03 | 22.92 | 16.14 | 9.3 | N/A | - | ||
| 2022/7 | 3.4 | 9.61 | 77.51 | 20.13 | 14.34 | 8.9 | N/A | 本月較同期增加主係膽固醇磷酸鹽結合劑歐洲客戶訂單增加及呼吸系統用藥接獲來自大陸客戶訂單所致。 | ||
| 2022/6 | 3.1 | 29.58 | 8.33 | 16.73 | 6.62 | 8.38 | N/A | - | ||
| 2022/5 | 2.39 | -16.95 | -4.78 | 13.63 | 6.24 | 8.7 | N/A | - | ||
| 2022/4 | 2.88 | -15.75 | -2.2 | 11.23 | 8.93 | 8.37 | N/A | - | ||
| 2022/3 | 3.42 | 65.71 | 35.0 | 8.35 | 13.4 | 8.35 | N/A | - | ||
| 2022/2 | 2.07 | -27.78 | -15.15 | 4.93 | 2.05 | 8.14 | N/A | - | ||
| 2022/1 | 2.86 | -10.97 | 19.57 | 2.86 | 19.57 | 9.18 | N/A | - | ||
| 2021/12 | 3.21 | 3.33 | -3.56 | 31.42 | 2.17 | 8.89 | N/A | - | ||
| 2021/11 | 3.11 | 21.04 | 49.73 | 28.21 | 2.87 | 8.47 | N/A | - | ||
| 2021/10 | 2.57 | -8.11 | -4.7 | 25.1 | -0.96 | 7.49 | N/A | - | ||
| 2021/9 | 2.8 | 31.27 | -0.38 | 22.53 | -0.51 | 6.84 | N/A | - | ||
| 2021/8 | 2.13 | 11.13 | -27.24 | 19.74 | -0.53 | 0.0 | N/A | - | ||
| 2021/7 | 1.92 | -33.1 | -20.62 | 17.61 | 4.07 | 0.0 | N/A | - |